In pharmaceutical regulation and policy, evidence-based policymaking uses a particular tool: the economic evaluation of drugs, where experts assess the cost of drugs relative to their therapeutic benefits, and make funding decisions on this basis. However, programs vary markedly in their goals (especially related to achieving value for money or standardizing access to care) and their mandates.
In a March 26 seminar titled Cost-effective drugs: paradigms and policies in Australia, Ontario, Canada, and the UK, Katherine Boothe, PhD, assistant professor of political science at McMaster, presents research comparing the adoption and reform of cost-effectiveness analysis programs in four jurisdictions.
The seminar will be held Wednesday March 26 in CRL B119, from 12:30 p.m. to 1:30 p.m. All are welcome to attend. The seminar will be available remotely for those who are unable to attend.
Boothe is an assistant professor of political science at McMaster who specializes in comparative public policy in advanced industrial democracies, with a focus on health policy. Her current research examines the development and reform of pharmaceutical insurance and regulatory policy in Canada, Australia, and the United Kingdom. She has a PhD and an MA in political science from the University of British Columbia.